5 High-Yield Pharmacy MCQs with Answers and Explanations | Clinical Pharmacy & Pharmacology Exam Preparation
Which of the following genetic testing might derive a potential benefit from trastuzumab therapy in a breast cancer patient?
A. TPMT positive activity
B. VKORC1 genotype positive
C. HER2/neu genotype positive
D. HLA-B *5801 genotype positive
C. HER2/neu genotype positive
Trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein. It is indicated only for patients with HER2-positive breast cancer (HER2 overexpression or gene amplification).
Testing for HER2 status (via immunohistochemistry or FISH) is required before starting trastuzumab, as only HER2-positive tumors derive significant benefit from the drug.
Why the other options are incorrect:
A. TPMT: Relevant for thiopurine drugs (e.g., azathioprine, 6-mercaptopurine) to predict risk of myelosuppression.
B. VKORC1: Influences warfarin dose requirements and bleeding risk.
D. HLA-B*5801: Associated with severe cutaneous reactions to allopurinol (especially in certain Asian populations).
Only HER2/neu positivity predicts potential benefit from trastuzumab therapy.
Important Clinical Pharmacy Point
Before initiating trastuzumab, breast cancer patients should undergo HER2 testing using:
- Immunohistochemistry (IHC): Evaluates HER2 protein expression.
- In situ hybridization (ISH/FISH): Evaluates HER2 gene amplification.
A 50-year-old Saudi woman with hypertension and dyslipidemia. She presented today to her follow up visit with family medicine clinic. Her sister has a type 1 diabetes mellitus. No alcohol or cigarette use is reported. She is physically active for 2 minutes a week.
Weight 51 kg Height 160 cm
Which of the following is a risk factor for developing diabetes type 2 in this patient?
A. Age
B. BMI
C. Gender
D. Family History
A. Age
Risk factor assessment in this patient:
Age (A): Age ≥45 years is a well-established risk factor for type 2 diabetes. At 50 years old, this applies.
BMI (B): Calculated BMI = 51 kg ÷ (1.60 m)² ≈ 19.9 (normal range). Obesity/overweight is a major risk factor, but she does not have it.
Gender (C): Female sex is not considered an independent risk factor for type 2 diabetes in standard screening criteria (men often have higher risk at comparable ages).
Family History (D): A first-degree relative with type 2 diabetes is a strong risk factor. Her sister has type 1 diabetes, which does not confer the same risk for type 2 diabetes.
Additional notes:
She does have other risk factors (hypertension, dyslipidemia, very low physical activity, and Middle Eastern ethnicity), but among the listed choices, age is the clear risk factor present in this patient.
Important Exam Pearl
Major risk factors for type 2 diabetes include:
1. Age ≥35 years.
2. Overweight or obesity.
3. Family history of type 2 diabetes in a first-degree relative.
4. Physical inactivity.
5. Hypertension.
6. Dyslipidemia.
7. History of gestational diabetes or PCOS.
An 88-year-old frail woman with osteoarthritis has difficulty in walking and pain. She has no other medical history and has failed numerous aids to help her with the pain. Which of the following drugs is the best recommendation?
A. Acetaminophen
B. Glucosamine D
C. Celecoxib
D. Ibuprofen
A. Acetaminophen
In an 88-year-old frail woman with osteoarthritis, acetaminophen is the safest and most appropriate first-line pharmacologic option among those listed.
Rationale:
Acetaminophen has a favorable safety profile in the elderly when used at recommended doses (typically ≤3 g/day in frail older adults). It lacks significant gastrointestinal, cardiovascular, and renal risks associated with NSAIDs.
Ibuprofen (non-selective NSAID) and celecoxib (COX-2 selective NSAID) both carry increased risks of GI bleeding, cardiovascular events, fluid retention, and renal impairment—risks that are substantially higher in frail elderly patients.
Glucosamine has limited and inconsistent evidence of meaningful benefit for osteoarthritis pain and is not strongly recommended in major guidelines.
Supporting context:
Major guidelines (including those from the American College of Rheumatology and similar bodies) have traditionally recommended acetaminophen as initial therapy for osteoarthritis pain in older adults, particularly when non-pharmacologic measures have failed. Although more recent data have questioned its overall efficacy, it remains the preferred choice here because of superior safety compared with the NSAID options.
Practical note: Use the lowest effective dose, monitor for rare hepatotoxicity (especially if there is any alcohol use or liver concerns), and reassess response. If pain remains uncontrolled, carefully consider other options (e.g., topical NSAIDs, duloxetine, or limited tramadol) with specialist input given her frailty.
An 18-year-old healthy girl admitted to the hospital with a diagnosis of necrotizing pneumonia. She received vancomycin 1 gm IV q12h and meropenem 1 gm IV q8h. The trough level of vancomycin was 16 mcg/ml (normal range: 10-20 mcg/ml).
Which of the following is the next appropriate step in management of this patient?
A. Continue the same treatment
B. Request a drug level for meropenem
C. Increase the dose of vancomycin to 2 gm IV q12h
D. Decrease the dose of vancomycin to 500 mg IV q12h
A. Continue the same treatment
The vancomycin trough level of 16 mcg/mL falls within the accepted therapeutic range (10–20 mcg/mL). For serious infections such as necrotizing pneumonia (where MRSA coverage is often needed), a trough of 15–20 mcg/mL is preferred; 16 mcg/mL is therefore appropriate.
The patient is an otherwise healthy 18-year-old, so renal function is expected to be normal and the current 1 g IV q12h regimen is producing a suitable level.
Meropenem levels are not routinely monitored in clinical practice.
Increasing the vancomycin dose (option C) risks toxicity without clear benefit.
Decreasing the dose (option D) would likely drop the trough below the target range for this infection.
Therefore the most appropriate next step is to continue the current regimen and monitor clinical response (and renal function) as usual.
Important Clinical Pharmacy Point
Current consensus guidelines recommend AUC-guided vancomycin monitoring rather than relying solely on trough concentrations for serious MRSA infections.
- Recommended AUC24/MIC target: 400–600 mg·h/L (assuming MIC = 1 mg/L).
- Trough concentrations alone may not accurately predict efficacy and toxicity.
An experiment on unknown drugs D-1. D-2, D3 and D4 show the following results:
D-1 low lipid solubility
D-2 high molecular weight
D-3 low degree of plasma protein binding
D-4 weak acidity
Which of the following is most likely to be excreted in breast milk?
A D-1 B D-2 C D-3 D D-4
C. D-3
Drug transfer into breast milk is favored by:
✒High lipid solubility
✒Low molecular weight
✒Low plasma protein binding (higher free/unbound fraction available to diffuse)
✒Weak basic nature (milk is slightly more acidic than plasma → ion trapping of bases)
Evaluating the given properties:
D-1 (low lipid solubility) → poorly crosses into milk
D-2 (high molecular weight) → poorly crosses into milk
D-3 (low plasma protein binding) → more free drug available → most likely to transfer into breast milk
D-4 (weak acidity) → weak acids tend to remain in plasma rather than concentrate in milk
Therefore, D-3 is the drug most likely to be excreted in breast milk.
Take-home message: A higher free (unbound) drug fraction increases the potential for transfer into breast milk.
📖
Disclaimer:
This educational post contains pharmacy and clinical pharmacology multiple-choice questions (MCQs) designed to support exam preparation for pharmacy students, PharmD candidates, and healthcare professionals preparing for NAPLEX, DHA, MOH, SPLE, HAAD, PEBC, and other pharmacy licensing examinations.
The questions, answers, and explanations are intended for educational and informational purposes only. They should not be considered a substitute for professional medical advice, clinical judgment, institutional protocols, or current evidence-based treatment guidelines.
Clinical recommendations may vary depending on individual patient characteristics, updated clinical guidelines, and local healthcare policies. Always consult authoritative references and qualified healthcare professionals before making clinical decisions.
PharmaAssist does not guarantee examination results or endorse self-diagnosis or self-medication.
By using this content, readers acknowledge that it is intended solely for educational and examination-preparation purposes.
0 Comments